» Articles » PMID: 26449459

Synthetically Modified MRNA for Efficient and Fast Human IPS Cell Generation and Direct Transdifferentiation to Myoblasts

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2015 Oct 10
PMID 26449459
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Synthetic mRNA transfection enables efficient and controlled gene expression in human cells, without genome integrations. Further, modifications to the mRNA and transfection protocol now allow for repeated transfection and long-term gene expression of an otherwise short-lived mRNA expression. This is mainly achieved through introducing modified nucleosides and interferon suppression. In this study we provide an overview and details of the advanced synthesis and modifications of mRNA originally developed for reprogramming. This mRNA allows for very efficient transfection of fibroblasts enabling the generation of high quality human iPS cells with a six-factor mRNA cocktail in 9 days. Furthermore, we synthesised and transfected modified MYOD1 mRNA to transdifferentiate human fibroblasts into myoblast-like cells without a transgene footprint. This efficient and integration-free mRNA technology opens the door for safe and controlled gene expression to reverse or redirect cell fate.

Citing Articles

Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine.

Inagaki M J Dev Biol. 2024; 12(1).

PMID: 38535481 PMC: 10971469. DOI: 10.3390/jdb12010001.


Transgene-free direct conversion of murine fibroblasts into functional muscle stem cells.

Qabrati X, Kim I, Ghosh A, Bundschuh N, Noe F, Palmer A NPJ Regen Med. 2023; 8(1):43.

PMID: 37553383 PMC: 10409758. DOI: 10.1038/s41536-023-00317-z.


Endothelial cell direct reprogramming: Past, present, and future.

Cho S, Aakash P, Lee S, Yoon Y J Mol Cell Cardiol. 2023; 180:22-32.

PMID: 37080451 PMC: 10330356. DOI: 10.1016/j.yjmcc.2023.04.006.


Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges.

Guerreiro S, Maciel P Cells. 2023; 12(4).

PMID: 36831205 PMC: 9954744. DOI: 10.3390/cells12040538.


mRNA vaccines: the most recent clinical applications of synthetic mRNA.

Kwon S, Kwon M, Im S, Lee K, Lee H Arch Pharm Res. 2022; 45(4):245-262.

PMID: 35426547 PMC: 9012156. DOI: 10.1007/s12272-022-01381-7.